Roche Gets Reprieve On Avastin For Breast Cancer With Delay At FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA extends user fee date in lieu of reaching decision on whether or not to pull the breast cancer approval for bevacizumab.